New #CochraneReview assesses the benefits and harms of #risedronate in the primary and secondary prevention of #osteoporotic #fractures for #postmenopausal women at lower and higher risk for fractures, respectively. https://t.co/JHzNkHN6GR https://t.co/O4p
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women - PubMed https://t.co/l3UVdjjetc
Lee la revisión completa aquí https://t.co/JJqadinRcj (6/6) #menopausia #osteoporosis
RT @FF_Network: New Cochrane Review presents what we know from the evidence up to 24 March 2021 about the effect of risedronate for prevent…
New Cochrane review: Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women https://t.co/N1wT7kl0rL https://t.co/LFGXDgMuyU
Risedronate for preventing fractures caused by osteoporosis in postmenopausal women For secondary prevention, risedronate 5 mg/day prevents non-vertebral fracture, and hip fractures. Compared to placebo, risedronate does not increase risk of serious AE h
New Cochrane Review presents what we know from the evidence up to 24 March 2021 about the effect of risedronate for preventing fractures caused by osteoporosis https://t.co/aEZ3kKQHsU
RT @KGHNHSLibrary: Risedronate for preventing fractures caused by osteoporosis in postmenopausal women https://t.co/npVDzoHAEa
Risedronate for preventing fractures caused by osteoporosis in postmenopausal women https://t.co/npVDzoHAEa